BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17697999)

  • 1. Ligand-induced structural transitions in ErbB receptor extracellular domains.
    Dawson JP; Bu Z; Lemmon MA
    Structure; 2007 Aug; 15(8):942-54. PubMed ID: 17697999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two EGF molecules contribute additively to stabilization of the EGFR dimer.
    Lemmon MA; Bu Z; Ladbury JE; Zhou M; Pinchasi D; Lax I; Engelman DM; Schlessinger J
    EMBO J; 1997 Jan; 16(2):281-94. PubMed ID: 9029149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The extracellular domains of ErbB3 retain high ligand binding affinity at endosome pH and in the locked conformation.
    Kani K; Park E; Landgraf R
    Biochemistry; 2005 Dec; 44(48):15842-57. PubMed ID: 16313187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A structure-based model for ligand binding and dimerization of EGF receptors.
    Klein P; Mattoon D; Lemmon MA; Schlessinger J
    Proc Natl Acad Sci U S A; 2004 Jan; 101(4):929-34. PubMed ID: 14732694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of the extracellular region of HER3 reveals an interdomain tether.
    Cho HS; Leahy DJ
    Science; 2002 Aug; 297(5585):1330-3. PubMed ID: 12154198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface.
    Dawson JP; Berger MB; Lin CC; Schlessinger J; Lemmon MA; Ferguson KM
    Mol Cell Biol; 2005 Sep; 25(17):7734-42. PubMed ID: 16107719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oligomers of ERBB3 have two distinct interfaces that differ in their sensitivity to disruption by heregulin.
    Kani K; Warren CM; Kaddis CS; Loo JA; Landgraf R
    J Biol Chem; 2005 Mar; 280(9):8238-47. PubMed ID: 15611073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function.
    Mattoon D; Klein P; Lemmon MA; Lax I; Schlessinger J
    Proc Natl Acad Sci U S A; 2004 Jan; 101(4):923-8. PubMed ID: 14732693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the nature of low- and high-affinity EGF receptors on living cells.
    Ozcan F; Klein P; Lemmon MA; Lax I; Schlessinger J
    Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5735-40. PubMed ID: 16571657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active and inactive conformations of the epidermal growth factor receptor.
    Ferguson KM
    Biochem Soc Trans; 2004 Nov; 32(Pt 5):742-5. PubMed ID: 15494003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational nanobodies reveal tethered epidermal growth factor receptor involved in EGFR/ErbB2 predimers.
    Nevoltris D; Lombard B; Dupuis E; Mathis G; Chames P; Baty D
    ACS Nano; 2015 Feb; 9(2):1388-99. PubMed ID: 25603171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.
    Li S; Schmitz KR; Jeffrey PD; Wiltzius JJ; Kussie P; Ferguson KM
    Cancer Cell; 2005 Apr; 7(4):301-11. PubMed ID: 15837620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization.
    Ferguson KM; Berger MB; Mendrola JM; Cho HS; Leahy DJ; Lemmon MA
    Mol Cell; 2003 Feb; 11(2):507-17. PubMed ID: 12620237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bivalence of EGF-like ligands drives the ErbB signaling network.
    Tzahar E; Pinkas-Kramarski R; Moyer JD; Klapper LN; Alroy I; Levkowitz G; Shelly M; Henis S; Eisenstein M; Ratzkin BJ; Sela M; Andrews GC; Yarden Y
    EMBO J; 1997 Aug; 16(16):4938-50. PubMed ID: 9305636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand binding induces a conformational change in epidermal growth factor receptor dimers.
    Walker F; Rothacker J; Henderson C; Nice EC; Catimel B; Zhang HH; Scott AM; Bailey MF; Orchard SG; Adams TE; Liu Z; Garrett TP; Clayton AH; Burgess AW
    Growth Factors; 2012 Dec; 30(6):394-409. PubMed ID: 23163584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complex relationship between ligand binding and dimerization in the epidermal growth factor receptor.
    Bessman NJ; Bagchi A; Ferguson KM; Lemmon MA
    Cell Rep; 2014 Nov; 9(4):1306-17. PubMed ID: 25453753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor mutant with wild-type affinity for both ErbB1 and ErbB3.
    Wingens M; Jacobs-Oomen S; van der Woning SP; Stortelers C; van Zoelen EJ
    Biochemistry; 2006 Apr; 45(14):4703-10. PubMed ID: 16584205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligand-binding enhances the affinity of dimerization of the extracellular domain of the epidermal growth factor receptor.
    Odaka M; Kohda D; Lax I; Schlessinger J; Inagaki F
    J Biochem; 1997 Jul; 122(1):116-21. PubMed ID: 9276679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of N-glycosylation in EGFR ectodomain ligand binding.
    Azimzadeh Irani M; Kannan S; Verma C
    Proteins; 2017 Aug; 85(8):1529-1549. PubMed ID: 28486782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into the evolution of the ErbB receptor family and their ligands from sequence analysis.
    Stein RA; Staros JV
    BMC Evol Biol; 2006 Oct; 6():79. PubMed ID: 17026767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.